Human papillomavirus 16/18 vaccine recombinant bivalent - Xiamen Innovax

Drug Profile

Human papillomavirus 16/18 vaccine recombinant bivalent - Xiamen Innovax

Alternative Names: Cecolin; Human papillomavirus (types 16 and 18) L1 virus-like particle vaccine - Xiamen Innovax; Human papillomavirus 16/18 bivalent vaccine recombinant - Xiamen; Human papillomavirus 16/18 vaccine - Xiamen; Recombinant human papillomavirus bivalent (type 16/18) vaccine - Xiamen Innovax

Latest Information Update: 20 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Xiamen Innovax Biotech
  • Developer Beijing Wantai Bio-pharm; Xiamen Innovax Biotech; Xiamen University
  • Class Cancer vaccines; Papillomavirus vaccines; Synthetic vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Cervical cancer; Human papillomavirus infections

Most Recent Events

  • 08 Jul 2014 Xiamen Innovax Biotech and Beijing Wantai Bio-pharm complete enrolment in a phase III trial in Human papillomavirus infections (Prevention, in volunteers) in China (NCT01735006)
  • 31 Jul 2011 Xiamen University completes a phase I trial in Human papillomavirus infections (prevention) in China (NCT01263327)
  • 17 Dec 2010 Phase-I clinical trials in Cervical cancer prevention in China (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top